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ABSTRACT (Word count 250)  
Background 
Prisoners are a priority group for hepatitis C (HCV) treatment.  Although treatment durations will 
become shorter using directly acting antivirals (DAAs), nearly half of prison sentences in Scotland are 
too short to allow completion of DAA therapy prior to release.  The purpose of this study was to 
compare treatment outcomes between prison- and community-based patients, and to examine the 
impact of prison release or transfer during therapy.   
Methods 
A national database was used to compare treatment outcomes between prison treatment initiates 
and a matched community sample.  Additional data were collected to investigate the impact of 
release or transfer on treatment outcomes.  Treatment naïve patients infected with genotype 
1/2/3/4 and treated between 2009 -12 were eligible for inclusion.      
Results and Conclusions  
291 prison initiates were matched with 1,137 community initiates: SVRs were 61% (95% CI 55% to 
66%) and 63% (95% CI 60% to 66%) respectively.  Odds of achieving a SVR were not significantly 
associated with prisoner status (p = 0.33). 
SVRs were 74% (95% CI 65% to 81%), 59% (95% CI 42% to 75%) and 45% (95% CI 29% to 62%) among 
those not released or transferred, transferred during treatment, or released during treatment 
respectively.  Odds of achieving a SVR were significantly associated with release (p<0.01), but not 
transfer (p=0.18).       
Prison-based HCV treatment achieves similar outcomes to community-based treatment, with those 
not released or transferred during treatment doing particularly well. Transfer or release during 




therapy should be avoided whenever possible, using anticipatory planning and medical holds where 





















Chronic hepatitis C is an important cause of liver-related morbidity and mortality worldwide. [1] 
People who inject drugs (PWID) are at increased risk of hepatitis C (HCV), and are also over-
represented within the judicial system, with global prevalence of HCV antibody among the prison 
population estimated to be 26%, and 64% among prisoners who report a history of injecting drug 
use. [2] With more than 10 million people incarcerated at any one time, [3] this equates to over 2 
million HCV antibody positive detainees worldwide. [2] Prisoners with HCV pose a considerable risk 
of onward transmission, through the use of non-sterile injecting equipment in a setting where 
needle exchange is limited or absent. [4] For this reason, the European Association for the Study of 
Liver Disease (EASL) has recommended that incarcerated individuals should be prioritised for HCV 
therapy. [5]   
In Scotland, approximately 1,500 prisoners have evidence of current or previous infection with HCV, 
[6] and it is estimated that over 70% of HCV antibody positive PWID have been incarcerated at some 
point. [7] Since the publication of treatment targets in the Hepatitis C Action Plan in 2008, [8] the 
proportion of treatment initiations in the prison setting has increased from 4% to 14% (translating to 
a seven-fold increase in treatment uptake). [9]  
This drive to increase treatment uptake has led to the development of dedicated prison-based HCV 
services, as well as a willingness to commence treatment in short-term prisoners who are likely to be 
released or transferred prior to their treatment completion date.  While a US study has reported on 
treatment outcomes among prisoners incarcerated for the full treatment duration, [10] no such 
investigation has hitherto examined treatment among prisoners whose release might pre-date 
treatment completion, or assessed the impact of inter-prison transfer.  The introduction of all-oral 
directly-acting antiviral (DAA) therapies will shorten the duration of HCV treatment from 24-48 to 8-
16 weeks of treatment, and reduce the incidence of side-effects. [11] However, nearly half of all 




prison sentences in Scotland are less than six months, [12] providing limited time for HCV testing, 
assessment, and treatment completion, even in the DAA era.  An added complexity is that treatment 
disruption due to prison transfer is set to increase, given the growing prison population and changes 
to the prison estate. [13].   
In the context of the potential benefits of DAAs [11] and the EASL recommendations on priority 
access for prisoners, the aim of this study was to compare treatment outcomes among prisoners and 
a matched population in the community, and to investigate factors (including prison release or 
transfer during therapy) that might be associated with adverse treatment outcomes.  Such 
information will inform future clinical guidance on treatment strategies for prison inmates.   
MATERIALS AND METHODS 
Hepatitis C treatment and care 
In Scotland, healthcare is delivered by fourteen geographically-defined Health Boards as part of a 
national universal service.  Health Boards are free to design their Hepatitis C services according to 
local population needs, although outcomes are monitored nationally through the Scottish 
Government Blood Borne Virus Framework and the HCV Outcome and Quality Indicators. [14, 15] 
The majority of treatment for HCV in Scotland is delivered by Specialist Nurse Practitioners overseen 
by Consultant Physicians, and is based in hospital clinics or delivered by a dedicated prison-liaison 
team.  This team develop close working relationships with prison staff, allowing early information 
sharing about potential prisoner release or transfer.  In the three Health Boards where additional 
data were collected, prisoners who need to continue treatment after release or transfer are referred 
(in writing and by telephone) to the receiving community- or prison-based service.  Addictions 
support, including opiate replacement therapy (ORT), is available to both prison and community 
patients, although prisoners may be prioritised within some Health Board areas for ORT treatment 
slots.      





In Part 1 of the study, the Scottish HCV Clinical Database was used to compare treatment outcomes 
between prison and community treatment initiates.  This database holds information on all patients 
treated for HCV at NHS clinics in Scotland (accounting for >95% of total treatment initiations).  
Health Boards with comprehensive data on both prison and community treatment initiations were 
included in the study i.e. NHS Forth Valley, Lothian, Greater Glasgow & Clyde, Tayside, Grampian, 
Fife, Lanarkshire, Borders, and Highlands.  
In Part 2, additional data were collected from medical records of prison treatment initiates in three 
Health Boards with the largest prisoner case-load (Forth Valley, Greater Glasgow and Clyde, and 
Lothian) to investigate factors associated with treatment completion and treatment outcome among 
this population.   
Inclusion criteria  
Patients were eligible for inclusion in Part 1 of the study if they were treatment-naive adults aged ≥ 
20 years infected with genotype 1, 2, 3, or 4, treated with PEG/RBV +/- a protease inhibitor, and 
were initiated on treatment after 1st June 2009 (when prisoner status started to be reliably reported 
on the clinical database) and before 1st December 2011 (genotypes 1 and 4) and 1st June 2012 
(genotypes 2 and 3), to allow adequate time for ascertainment of treatment outcomes.  
Patients were eligible for inclusion in Part 2 of the study if they met all of the inclusion criteria 
applying to Part 1 of the study, and had initiated treatment in prison in one of the three selected 
Health Board areas.   
Definitions of Treatment Outcomes  
Treatment completion: reached the end of planned course of therapy, regardless of whether 
attended for SVR check 




SVR: undetectable HCV RNA at 24 weeks post treatment completion  
Relapse: HCV RNA negative at treatment completion, but subsequently HCV RNA positive at 12-24 
weeks post treatment completion. 
No response: HCV RNA detectable at end of treatment   
Data analysis 
Part 1: 
Patient characteristics were compared between patients who initiated HCV treatment in prison, and 
patients who initiated treatment in the community (for both the total community sample, and the 
matched community sample).     
Variable ratio matching was used to match each prison treatment initiate with up to five community 
initiates.  Matching was based on age at treatment commencement, sex, treatment type, cirrhosis 
status at or within 30 days of treatment commencement, and HCV genotype.  Matching on 
categorical variables was exact, and matching on continuous variables was optimal, using 
mahalanobis distance scores.  Variable ratio matching may lead to differences in characteristics 
between the prison and the matched community sample, which can be adjusted for in further 
analysis.    
The odds of achieving a SVR among prison treatment initiates compared to community initiates were 
calculated for all patients and by genotype (GT 1/4 and GT 2/3), using conditional logistic regression 
to account for the matched study design.  Two different populations were used for analysis: the 
intention to treat population (ITT), (i.e. all patients who received at least one dose of treatment, 
regardless of whether they were followed-up) and the per protocol population (i.e. all patients 
where the outcome of treatment was known).  An unmatched logistic regression was conducted as a 
sensitivity analysis.    





The characteristics of patients initiated on therapy in prison were compared between those who did 
and did not complete treatment, and who did or did not achieve a SVR (using both the ITT and the 
per protocol population).  Because some prisoners were both transferred and released from prison 
during treatment (and release was considered to be more important in determining treatment 
outcome), a hierarchical variable was created as follows: i) neither released nor transferred, ii) 
transferred but not released, and iii) released, whether transferred or not.     
Logistic regression was used to investigate factors associated with completing treatment, and 
achieving a SVR, for all patients, and by genotype.  An additional variable ‘Intention to complete 
treatment in prison’ presented in the univariate analysis was not included in the multivariate 
analysis, due to a high degree of correlation with the ‘Released during treatment’ variable.       
Ethical approval 
A submission was made to the South East Scotland Research Ethics Committee (application 
14/WM/1045), who advised that ethical submission was not required for this study.   
RESULTS  
Part 1: Matched analysis of Scottish clinical database 
There were 2,657 individuals who met the study inclusion criteria: 291 initiated treatment in prison, 
and 2,366 initiated treatment in the community.  Characteristics of the 291 prison initiates and the 
matched 1,137 community ‘controls' are shown in Table 1.  More than 90% of initiates in both 
treatment settings were treated with PEG/RBV alone.   
Treatment outcomes  
SVRs were 61% (95% confidence interval [CI] 55% to 66%) among patients initiated on treatment in 
prison, compared to 63% (95% CI 60% to 66%) among patients initiated on treatment in the 




community.  The odds of achieving a SVR were not significantly associated with prisoner status at 
treatment initiation, whether calculated using conditional logistic regression (odds ratio [OR] 0.87, 
95% CI 0.67, 1.15; p = 0.33), or unmatched logistic regression (OR 0.90, 95% CI 0.70, 1.17; p = 0.45) 
(Appendix 1).  The same findings were observed when stratified by genotype (Table 2 and Appendix 
1).     
Part 2: Additional data collection from selected Health Board prison clinics 
The characteristics of the 200 patients included in the additional data collection were comparable to 
the total population of prison treatment initiates in Part 1 of the study, except for a slightly higher 
proportion of younger prisoners in the subsample (56% were aged 20-39 years in the total prisoner 
population, compared to 66% in the subsample) (Table 3).   
Treatment intentions  
Of 200 prisoners initiating treatment, 128 (64%) intended to complete treatment while incarcerated, 
38 (19%) intended to complete treatment in the community, and 34 (17%) had unknown treatment 
intentions.  Of the 128 patients intending to complete treatment in prison, 43 (34%) had GT1/4 
infection and 85 (66%) had GT2/3 infection.  Ninety-eight (77%) remained in prison for the full 
treatment duration, 22 (17%) were transferred, and 8 (6%) were released during treatment.  Of the 
38 patients intending to complete treatment in the community, 22 (58%) had GT1/4 infection and 16 
(42%) had GT2/3.   
Prison transfer and release 
Among the 200 prisoners, 125 (63%) remained in the same prison for the full treatment duration, 37 
(19%) were transferred but not released, and 38 (19%) were released during treatment.  Among the 
38 individuals released during treatment, this was a planned event for 28 (74%), and not planned or 
not known for 10 (26%) prisoners.   




SVRs were 74% (95% CI 65% to 81%) for those not released or transferred, 59% (95% CI 42% to 75%) 
for those transferred, and 45% (95% CI 29% to 62%) for those released during treatment.  Using per 
protocol analysis (excluding individuals where the SVR outcome was not known), SVRs were 84% 
(95% CI 75% to 90%) among those not released or transferred, 81% (95% CI 62% to 94%) among 
those transferred, and 74% (95% CI 52% to 90%) among those released during treatment (Appendix 
2).      
Factors associated with treatment completion  
Of the 200 prisoners, 147 (74%, 95% CI 67% to 80%) completed a full course of treatment and 35 
(18%) did not.  Treatment completion status was not known for 18 (9%) individuals: for the purposes 
of logistic regression it was assumed that these individuals had not completed treatment.  In the 
multivariate analysis including all genotypes, treatment completion was significantly associated with 
cirrhosis status (OR 0.16, 95% CI 0.03, 0.81, p=0.03), being transferred during treatment (OR 0.41, 
95% CI 0.17, 1.00, p =0.05), or being released during treatment (OR 0.10, 95% CI 0.04, 0.24, p <0.01) 
(Table 4).  
Factors associated with achieving a SVR 
Of the 200 prisoners, 131 (66%, 95% CI 59% to 72%) achieved a SVR, and 27 (14%) did not.  SVR 
status was unknown for 42 individuals (21%): for the purposes of logistic regression it was assumed 
that these individuals did not achieve a SVR.  In the multivariate analysis, achieving a SVR was 
significantly associated with GT 2/3 (OR 2.1, 95% CI 1.12, 3.90, p =0.02) and being released from 
prison during treatment (OR 0.33, 95% CI 0.15, 0.71, p < 0.01), but not with transfer during 
treatment (OR 0.58, 95% CI 0.26, 1.27, p=0.18) (Table 4).   
 
 





The use of prison-based treatment programmes for chronic HCV has become an increasingly 
important strategy in recent years, with the publication of a number of prioritisation statements and 
treatment targets relating to prison healthcare. [5, 8, 16, 17] The results of this study suggest that 
HCV treatment in the prison setting is both feasible and effective.  Among nearly 1,500 individuals 
treated for HCV, outcomes were similar for prison-initiates (61% [95% CI 55% to 66%]) and a 
matched sample in the community (63% [95% CI 60% to 66%]).  For those prison-initiates who were 
not released or transferred during therapy, outcomes appeared to be even better than for 
community initiates (although the two groups could not be matched and are therefore not directly 
comparable): SVRs were 61% (95% CI 47% to 74%) for GT1/4, and 75% (66% to 83%) for GT2/3 in the 
prison setting, compared to 56% (95% CI 51% to 60%) for GT1/4, and 68% (64% to 71%) for GT2/3 in 
the community.  A previous study that restricted treatment to prisoners incarcerated for the full 
treatment duration found similar outcomes between prison- and community-based patients, but 
their prison population were more likely to have advanced liver disease. [10]  
The observed benefits of prison-based therapy are likely to be related to improved treatment 
compliance within the prison regime, which is of particular relevance to the DAA era and the 
increased risk of viral resistance compared to standard PEG/RBV regimens. [18] The findings are 
consistent with recent cost-effectiveness studies of HCV case-finding in prisons. Short prison 
sentences and a lack of continuity of care between prison and the community attenuate the cost-
effectiveness of case-finding initiatives in prisons, based on traditional PEG/RBV regimens.  However, 
case-finding may become cost-effective in the DAA era, because treatment is more likely to be 
completed during the prison sentence [19, 20].  
 




 Our results suggest that prison-based treatment programmes should be encouraged, both as a 
means of improving population health (given that the majority of HCV-infected PWID will pass 
through the prison system at some point [7]), and of offering individuals the best possible chance of 
achieving a SVR.   
However, it is evident that prison-based treatment is not without its challenges.  In this study, nearly 
40% of prisoners were either released or transferred during HCV therapy, and outcomes were 
poorer for these individuals.  This pattern was observed among both GT1/4 and GT2/3 patients, and 
was still evident (although attenuated) using per protocol analysis, suggesting that only part of this 
difference is due to increased loss to follow-up or failure to attend for a final SVR check among those 
who are transferred or released (Appendix 2, 3, and 4).     
Poorer treatment outcomes among transferred prisoners raise a number of issues for both 
healthcare providers and custodial staff.  In contrast to prisoners who are released, transferred 
prisoners remain under the care of the prison system, and any unplanned interruption in therapy is 
by definition the responsibility of the system, rather than the patient.  Transferring prison not only 
means a change in regime (potentially changing the timing of medication and access to or timing of 
clinical review), but also a change of healthcare staff, and the need to build new relationships mid-
way through a course of therapy.  For this reason, our results suggest that transfer during treatment 
should be prevented wherever possible, using a policy of medical hold (whereby prisoners receiving 
a course of medical treatment are prohibited from moving prison, except for security reasons) if 
necessary.  The use of medical holds may be inconsistently applied and may in some cases 
disadvantage a prisoner who wishes to transfer for family reasons or training opportunities. [22] 
However, their use may be sensible in situations where the prisoner has made an informed decision 
to forgo any potential benefits of transfer while treatment is being completed.  For those situations 
where transfer is obligatory, healthcare services may wish to agree a set of minimum requirements 




for prison transfers (e.g. such as provision of a minimum quantity of medication, and maximum 
waiting times for an appointment with the receiving team).   
Poorer treatment outcomes in this study among those released during therapy are also concerning, 
and it may be prudent in some cases to delay treatment until after a prisoner’s release.  Decisions 
need to be made on a case by case basis, taking into account the duration of incarceration, 
willingness to commence treatment, and the existence of any support structures after release.  
There is currently a lack of published evidence in this area, but a number of factors are likely to 
contribute to treatment completion post-release; including strong family support, stable housing 
and employment, and links to other healthcare providers in the community.  Patient motivation 
through provision of test results that demonstrate improvements in liver function (e.g. fibroscan 
results or liver function tests) [23] might also be helpful.   
In a small number of cases, release during treatment may be an unexpected event; for example, if a 
prisoner is released directly from a court hearing.  In this study, only 6% of patients who intended to 
complete treatment while incarcerated were actually released prior to completion, suggesting that 
healthcare practitioners have sufficient knowledge of prisoner trajectory when treatment is started.  
However, it may still be of value to agree contingency plans for prisoners where incarceration for the 
full treatment period cannot be guaranteed; for example seeking the prisoner’s permission for HCV 
services to contact their GP, a close family member, or Addictions Services in the event that they are 
released and lost to follow-up.  Developing close links with Addictions Services may be particularly 
useful, given that those on OST programmes are much more likely to stay in touch with services.    
Finally, the risk of reinfection among prisoners following treatment has been shown to be 
considerable. [24] For those still incarcerated, the greatest risk lies in the continuation of injecting 
practice in a setting where needle exchange provision may be limited or absent. [4] For those 
released, there may be a return to old behaviours and injecting partners, many of whom will not 




have had the benefit of priority access to HCV treatment while in prison.  Treatment guidelines 
suggest that the risk of reinfection should be fully explained, and that patients should be counselled 
on ways to minimize this risk, [5, 17] although there is currently a lack of evidence around how this 
counselling can be effectively delivered.     
This study has demonstrated that prison-based treatment is feasible, and achieves comparable or in 
some cases even better outcomes than community-based treatment.  However, treatment in the 
prison setting is not without its challenges, particularly with respect to transfer and release from 
prison while therapy is ongoing.  Treatment disruption due to release or transfer needs to be 
prevented wherever possible, while ensuring that contingency measures to maximise treatment 
success are in place where transfer or release is unavoidable.   
 
ACKNOWLEDGEMENTS AND DISCLOSURES  
MH acknowledges support from the National Institute for Health Research Health Protection 
Research Unit (NIHR HPRU) in Evaluation of Interventions at University of Bristol.  
NM acknowledges support from the National Institute for Drug Abuse [grant number R01 DA037773-
01A1] and University of California San Diego Center for AIDS Research (CFAR), a National Institute of 
Health (NIH) funded program [grant number P30 AI036214]. The views expressed are those of the 
authors, and not necessarily those of the UK NHS, the UK NIHR or the UK Department of Health 
The authors would like to acknowledge the Clinical Database Monitoring Committee, the Clinical 
Database data entry staff at the participating NHS Health Boards, and the Scottish Government for 
funding the Scottish Clinical Database.   
JD has received honoraria for lectures, advisory panels, and support to attend conferences from 
Janssen, Roche, MSD, Gilead, BMS, Boeringer Ingelheim, and his institution has received grants for 
research from Janssen, Roche, MSD, Gilead, and BMS.  SL has been on the nurse advisory board for 
Abbvie and BMS.  DJG has received honoraria for educational contributions (e.g. lectures, reports) 
and for providing advice on aspects of Hepatitis C and public health from Abbvie, Merck, Gilead, 
BMS, and Janssen.  MH has received unrestricted research grants as co-investigator from Gilead and 
honoraria from Gilead and Janssen. NM has received unrestricted research grants from Gilead 
unrelated to this work and honoraria from Merck, AbbVie, and Janssen. All other authors declare 
that they have no conflicts of interest in relation to this manuscript. 
 




AUTHOR CONTRIBUTIONS  
EJA, SJH & DJG designed the study; WM, JS, AC, SL, SEP & PB conducted the data collection; HV & HI 
provided the clinical database extract, EJA conducted the data analysis drafted the manuscript; PRM, 
SB, AF & JD are members of the Scottish Clinical Database Monitoring Committee; SJH supervised 




























1. Lavanchy D.  The global burden of hepatitis C.  Liver International, 2009; 29 (s1): 74-81 
2. Larney S, Kopinski H, Beckwith C.G et al.  The incidence and prevalence of hepatitis C in 
prisons and other closed settings: Results of a systematic review and meta-analysis.  
Hepatology, 2013; 58: 1215-1224   
3. Walmsley R.  World Prison Population List (tenth edition).  International Centre for Prison 
Studies.  International Centre for Prison Studies, 2013.  Accessed online 2nd June 2015, URL: 
http://prisonstudies.org/sites/prisonstudies.org/files/resources/ downloads/wppl_10.pdf 
4. Hunt DR, Saab S.  Viral hepatitis in incarcerated adults: a medical and public health concern.  
Am J Gastroenterol, 2009; 1024-31   
5. European Association for the Study of Liver Diseases.  EASL Clinical Practice Guidelines, 2015.   
6. Taylor A, Munro A, Allen E et al.  Low incidence of hepatitis C virus among prisoners in 
Scotland.  Addiction, 2013; 108: 1296-304  
7. University of the West of Scotland, Health Protection Scotland, University of Strathclyde, and 
the West of Scotland Specialist Virology Centre.  The Needle Exchange Surveillance Initiative 
(NESI): Prevalence of HCV and injecting risk behaviours among people who inject drugs 
attending injecting equipment provision services in Scotland, 2008/2009 & 2010.  University 
of the West of Scotland, September 2012 
8. Scottish Government.  Hepatitis C Action Plan for Scotland: Phase II: May 2008 – March 
2011.  Scottish Government, 2008.  Accessed online 27th October 2014, URL: http://www. 
scotland.gov.uk/Resource/Doc/222750/0059978.pdf 
9. Public Health England.  Hepatitis C in the UK: 2014 Report.  Accessed online 18th June 2014, 
URL: https://www.gov.uk/government/uploads/system/uploads /attachment_data/file/ 
337115/HCV_in_the_UK_2014_24_July.pdf 
10. Rice JP, Burnett D, Tsotsis H et al.  Comparison of Hepatitis C Virus Treatment Between 
Incarcerated and Community Patients.Hepatology, 2012; 56: 1252-1260 
11. Kohli A, Shaffer A, Sherman A, Kottilil S.  Treatment of Hepatitis C: A Systematic Review.  
JAMA, 2014; 312: 631-640  
12. Scottish Government.  Statistical Bulletin Crime and Justice Series: Prison Statistics Scotland: 
2012-13.  Accessed online 30th September 2015, URL: http://www.gov.scot /Topics/ 
Statistics/Browse/CrimeJustice/ Datasets/PrisonsDatasets/prisdata1213 
13. Audit Scotland.  Managing increasing prisoner numbers in Scotland.  Audit Scotland, May 
2008.  Accessed online 8th June 2015, URL: http://www.audit-scotland.gov.uk/ docs/central/ 
2008/ nr_ 080508_prisoner_numbers.pdf  
14. Scottish Government.  The Sexual Health and Blood Borne Virus Framework 2011-15.  
Accessed online 1st June 2015, URL:http://www.gov.scot/Resource/Doc/356286/ 
0120395.pdf     
15. Healthcare Improvement Scotland.  Quality Indicators for Hepatitis C, APRIL 2012.  Accessed 
online 5th May 2015, URL:http://www.healthcareimprovementscotland.org /our_work/ 
long_term_conditions/hepatitis_c/hepatitis_c_quality_indicators.aspx   
16. Ministerial Advisory Committee on AIDS, Sexual Health and Hepatitis, Hepatitis C 
Subcommittee.  Hepatitis C Prevention, Treatment and Care: Guidelines for Australian 
Custodial Settings, 2008.  Accessed online 12th August 2015, URL: 






17. American Association for the Study of Liver Diseases.  Recommendations for Testing, 
Managing, and Treating Hepatitis C.   
18. Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E.  Update on hepatitis C 
virus resistance to direct-acting antiviral agents.  Antiviral Res, 2014; 108: 181-191  
19. Martin NK, Hickman M, Miners A, Hutchinson SJ, Taylor A, Vickerman P. Cost-effectiveness 
of HCV case-finding for people who inject drugs via dried blood spot testing in specialist 
addiction services and prisons. BMJ Open, Aug 2013; 3(8) 
20. Martin NK, Vickerman P, Brew IF, Williamson J, Miners A, Irving WL, et al.  Is increased 
hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting 
antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.  Hepatology, 
2016; 63: 1796-1808 
21. United Nations Human Rights.  Basic Principles for the Treatment of Prisoners, 1990.  
Accessed online 12th August 2015, URL:http://www.ohchr.org/EN/Professional 
Interest/Pages/BasicPrinciplesTreatmentOfPrisoners.aspx 
22. Humphreys C, Lombard M, Newton A, O’Moore E, Railton C.  An audit of hepatitis C services 
in a representative sample of English prisons.  Public Health England and Department of 
Health, 2013.  Accessed online 21st July 2015, URL:https://www.gov. uk/government/ 
uploads/system/uploads/attachment_data/file/337401/An_audit_of_hepatitis_C_services_i
n_a_representative_sample_of_English_prisons_2013.pdf  
23. Vergniol J, Foucher J, Castera L et al.  Changes of non-invasive markers and FibroScan values 
during HCV treatment.  Journal of Viral Hepatitis, 2009; 16: 132-140  
24. Marco A, Esteban JI, Sole C et al.  Hepatitis C virus reinfection among prisoners with 
sustained virological response after treatment for chronic hepatitis C.  Journal of 

























Table 1: Characteristics of 2,657 patients (291 prison-based and 2,366 community-based) commencing 
Hepatitis C treatment 2009-2012, by incarceration status  
 Commenced treatment 
in prison 
(n= 291) 
Commenced treatment in community  









Major HCV genotype 




Diagnosed with cirrhosis 


















































































Treatment outcome by genotype 







































* Community-based sample were matched on age at treatment commencement, sex, treatment type, cirrhosis status at or within 30 days 




Table 2: Conditional logistic regression of the odds of SVR by prisoner status, among i) the intention to treat 
population, and ii) the population where the outcome of treatment is known 
 Intention to treat population Population where outcome of treatment is known 














































*Matched on age at treatment commencement, sex, treatment type, cirrhosis status at or within 30 days of treatment commencement, 
and HCV genotype 
 
 




Table 3: Characteristics of 200 patients commencing Hepatitis C treatment in prison in three large Health 
Board areas, 2009-2012  









known a  
 












Age d  
20-29 years 
30-39 years 





 Major HCV genotype 
1 or 4 








Drug injecting history 
Within last one year 
More than one year ago 
Never/unknown 




Treatment intentions e 
Intend to complete in prison 
Intend to complete in community 
Not known 
Prison sentence 
< 4 years 
≥ 4 years 
Not known 
Movement during treatment 
None 
Transferred but not released 

























































































































































































































































































Patients with GT 1/4 
 






































Patients with GT 2/3 
 






































a Treatment completion status not known for 18 (9%) cases; b  Treatment outcome not known for 42 (21%) cases; c p value refers to 
comparison between proportion ‘Yes’ and proportion ‘No/not known’; d At treatment commencement; e ‘Intention to complete treatment 
in prison’ was not included in the multivariate model, due to correlation with ‘Released during treatment’  










Table 4: Logistic regression of odds of treatment completion and SVR among 200 patients who commenced 
Hepatitis C treatment in prison, and stratified by genotype 
Patient characteristics Odds of completing treatment Odds of achieving a SVR 
Adjusted odds ratio p value Adjusted odds ratio p value 
ALL GENOTYPES 
Major HCV genotype 
1 or 4 




Movement during treatment 
None 
Transferred but not released 




1.75 (0.85, 3.58)  
 
1 
0.16 (0.03, 0.81) 
 
1 
0.41 (0.17, 1.00) 















2.09 (1.12. 3.90) 
 
1 
0.31 (0.06, 1.46) 
 
1 
0.58 (0.26, 1.27) 
















Movement during treatment 
None 
Transferred but not released 




0.33 (0.19, 5.89) 
 
1 
1.17 (0.30, 4.47) 












0.50 (0.29, 8.71) 
 
1 
0.50 (0.16, 1.59) 













Movement during treatment 
None 
Transferred but not released 




0.12 (0.01, 0.97) 
 
1 
0.17 (0.05, 0.56) 












0.24 (0.04, 1.52) 
 
1 
0.66 (0.22, 1.99) 









*At the time of treatment commencement 
 
 
